Table 1.

Baseline characteristics of participants across quartiles of CXCL9 at Visit 3

	10.00 ≤ Q1 < 107.31 (N = 75)	107.31 ≤ Q2 < 160.64 (N = 75)	160.64 ≤ Q3 < 246.59 (N = 75)	246.59 ≤ Q4 < 857.00 (N = 75)	p for trend
Age (years)	76.92 ± 4.47	78.08 ± 4.65	79.20 ± 4.54	82.33 ± 5.87	< .001
BMI (kg/m2)	26.65 ± 3.18	27.53 ± 3.49	26.94 ± 4.32	26.47 ± 4.17	0.565
Any prevalent fractures before V3, n (%)	48 (64.00)	50 (66.67)	43 (57.33)	43 (57.33)	0.244
Chair stands (n)	4.76 ± 1.63	4.18 ± 1.74	4.26 ± 1.68	3.79 ± 1.95	0.002
6 m walking speed (m/sec)	1.21 ± 0.20	1.12 ± 0.22	1.13 ± 0.21	1.05 ± 0.25	< .001
Multimorbidity Index score	0.93 ± 0.95	1.05 ± 1.09	1.05 ± 1.21	1.01 ± 0.99	0.662
PASE score	142.23 ± 69.30	142.07 ± 66.88	142.80 ± 53.11	117.78 ± 52.35	0.023
Total hip, BMD (g/cm2)	0.94 ± 0.13	0.95 ± 0.17	0.93 ± 0.14	0.92 ± 0.17	0.296
Femoral neck, BMD (g/cm2)	0.76 ± 0.13	0.78 ± 0.14	0.75 ± 0.12	0.76 ± 0.15	0.485
History of falls in the last 12 months, n (%)	12 (16.00)	23 (30.67)	17 (22.67)	26 (34.67)	0.034
% fat from DXA	26.63 ± 4.85	27.92 ± 4.40	25.19 ± 5.69	26.60 ± 5.95	0.320
CXCL9 (pg/ml)	80.06 ± 18.50	132.68 ± 15.28	197.37 ± 23.12	377.40 ± 147.17	< .001
CRP (ug/ml)	1.37 ± 1.75	2.99 ± 3.98	3.17 ± 4.72	3.15 ± 3.42	0.004
IL-1β (pg/ml)	0.04 ± 0.08	0.05 ± 0.12	0.08 ± 0.19	0.06 ± 0.09	0.187
IL-6 (pg/ml)	1.01 ± 0.58	2.36 ± 6.00	2.18 ± 3.97	1.72 ± 1.11	0.308
TNFα (pg/ml)	4.89 ± 1.35	5.41 ± 1.49	5.96 ± 1.57	6.15 ± 1.98	< .001

Values are presented as mean ± standard deviation, or number (%)

BMD, bone mineral density; BMI, body mass index; CRP, C-reactive protein; CXCL9, CXC motif chemokine ligand 9; DXA, dual-energy X-ray absorptiometry; IL-1β, interleukin-1beta; IL-6, interleukin-6; PASE, physical activity scale for the elderly; TNFα, tumor necrosis factor alpha; V3, visit 3